You are here

Home » Content

Plazma Goblet Hücre ve Ekzokrin Pankreas Antikor Sıklığının Crohn Hastalığı ve Ülseratif Kolit Ayırımındaki Klinik Değeri

The clinical impact of plasma goblet cell and exocrine pancreas antibodies in discriminating Crohn’s disease and ulcerative colitis

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objectives: Despite the increasing incidence of inflammatory bowel diseases (IBD) it may be challenging sometimes to discriminate Crohn’s disease (CD) and ulcerative colitis (UC). Although antibodies to exocrine pancreas (PAB) and Goblet cells (GAB) have been reported to have a low sensitivity and specificity for IBD no study has been performed yet in our country. Our aim was to determine the clinical importance of PAB and GAB in discriminating CD and UC. Methods: Sera of age- sex matched 130 healthy controls (HC), 102 UC, 63 CD patients followed-up at Istanbul University, Cerrahpafla Medical Faculty weekly IBD outpatient clinic were analysed. PAB and GAB were detected by indirect immunofluorescence assay (IFA). Results: The prevalence of GAB was 22/130 (17%), 27/102 (27%), 8/63 (13%) and the prevalence of PAB was 1/130 (0.8%), 2/102 (2%), 8/63 (13%) in HC, UC, CD patients, respectively. When all groups were compared to each other the prevalence of PAB was significantly higher in CD patients compared to HC (χ2=13.503; p= 0.000), and UC patients (p= 0.007), whereas the prevalence of GAB was significantly higher among UC patients compared to CD patients (χ2=4.420; p= 0.036). No significant difference regarding GAB was observed between UC patients and HC. The prevalence of GAB(+)/PAB(-) profile was 22/130 (17%), 26/102 (25%), 6/63 (10%) in HC, UC, CD patients, respectively. When CD patients were compared to UC patients the sensitivity, and specificity of this profile as a marker of CD was 0.25, and 0.84, respectively. The prevalence of GAB(-)/PAB(+) profile was 1/130 (0.7%), 1/102(1%), 6/63 (10%) in HC, UC, CD patients, respectively. When UC patients were compared to CD patients the sensitivity, and specificity of this profile as a marker of UC was 0.10, and 0.99, respectively. No significant correlations were observed between PAB, and GAB and location, clinical activity, the presence of prior resections, acute phase reactants, age, and sex in CD, and UC patients. Conclusion: Although the prevalences of GAB and PAB may vary in different IBD subgroups, the low sensitivity of both markers make them an useless tool in discriminating CD and UC.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-plazma-goblet-hucre-ekzokrin-pankreas-antikor-sikliginin-crohn-hastaligi-ulseratif-kolit-ayirimindaki-klinik-degeri.pdf
  • 1
27-32
  • Turkish

REFERENCES

References: 

1. Hugot JP, Chamaillard M, Zouali H, et al. Association
of NOD2 leucine-rich repeat variants with susceptibility
to Crohn’s disease. Nature 2001; 411: 599-603.
2. Vermeire S, Van Assche G, Rutgeerts P. C-reactive
protein as a marker for inflammatory bowel disease.
Inflamm Bowel Dis 2004; 10: 661-665.
3. Lennard-Jones JE. Classification of inflammatory
bowel disease. Scand J Gastroenterol 1989; 170
(Suppl.): 2-6.
4. Nayar M, Rhodes JM. Management of inflammatory
bowel disease. Postgrad Med J 2004; 80: 206-13.
5. Vermeire S, Peeters M, Rutgeerts P. Diagnostic
approach to IBD. Hepatogastroenterology 2000;
47: 44-48.
6. Malchow H, Ewe K, Brandes JW, et al. European
Cooperative Crohn's Disease Study (ECCDS): results
of drug treatment. Gastroenterology 1984; 86: 249-
266.
7. Rachmilewitz D. Coated mesalazine (5-aminosalicylic
acid) versus sulphasalazine in the treatment of
active ulcerative colitis: a randomised trial. BMJ
1989; 298: 82-86.
8. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura
M. An index of disease activity in patients with ulcerative
colitis. Am J Gastroenterol 1992; 87: 971-976.
Cerrahpafla T›p Derg 2008; 39(1): 27-32
9. Best WR, Becktel JM, Singleton JW, Kern F Jr.
Development of a Crohn's disease activity index.
National Cooperative Crohn's Disease Study.
Gastroenterology 1976; 70: 439-44.
10. Quinton JF, Sendid B, Reumaux D, et al. Anti-
Saccharomyces cerevisiae mannan antibodies combined
with antineutrophil cytoplasmic autoantibodies
in inflammatory bowel disease: prevalence and diagnostic
role. Gut 1998; 42: 788-91.
11. Peeters M, Joossens S, Vermeire S, et al. Diagnostic
value of anti-Saccharomyces cerevisiae and antineutrophil
cytoplasmic autoantibodies in inflammatory
bowel disease. Am J Gastroenterol 2001; 96: 730-734.
12. Joossens S, Reinisch W, Vermeire S, et al. The value
of serologic markers in indeterminate colitis: a
prospective follow-up study. Gastroenterology 2002;
122: 1242-7.
13. Fricke H, Birkhofer A, Folwaczny C, Mesiter W,
Scriba PC. Characterization of antigens from the
human exocrine pancreatic tissue (Pag) relevant as
target antigens for autoantibodies in Crohn’s disease.
Eur J Clin Invest 1999; 29: 41-45.
14. Seibold F, Mork H, Tanza S, et al. Pancreatic autoantibodies
in Crohn's disease: a family study. Gut 1997;
40: 481-484.
15. Seibold F, Weber P, Jenss H, Wiedmann KH.
Antibodies to a trypsin sensitive pancreatic antigen in
chronic inflammatory bowel disease: specific markers
for a subgroup of patients with Crohn's disease. Gut
1991; 32: 1192-7.
16. Klebl FH, Bataille F, Huy C, et al. Association of antibodies
to exocrine pancreas with subtypes of Crohn's
disease. Eur J Gastroenterol Hepatol 2005; 17: 73-77.
17. Koutroubakis IE, Drygiannakis D, Karmiris K, et al.
Pancreatic autoantibodies in Greek patients with
inflammatory bowel disease. Dig Dis Sci 2005; 50:
2330-2334.
18. Lawrance IC, Hall A, Leong R, et al. comparative
study of goblet cell and pancreatic exocine autoantibodies
combined with ASCA and pANCA in Chinese
and Caucasian patients with IBD. Inflamm Bowel Dis
2005; 11: 890-897.
19. Folwaczny C, Noehl N, Tschöp K, et al. Goblet cell
autoantibodies in patients with inflammatory bowel
disease and their first-degree relatives.
Gastroenterology 1997; 113: 101-106.
20. Hibi T, Ohara M, Kobayashi K, et al. Enzyme linked
immunosorbent assay (ELISA) and immunoprecipitation
studies on anti-goblet cell antibody using a
mucin producing cell line in patients with inflammatory
bowel disease. Gut 1994; 35: 224-230.

Thank you for copying data from http://www.arastirmax.com